|
Activity Number:
|
535
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Thursday, August 2, 2007 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Section on Health Policy Statistics
|
| Abstract - #310106 |
|
Title:
|
Update on Cardiometabolic Risk Reduction: Role of the Endocannabinoid System
|
|
Author(s):
|
Samer Ellahham*+ and Yasmin H. Said and Edward Wegman
|
|
Companies:
|
Innovative Medical Institute/Paragon Cardiovascular Foundation and George Mason University and George Mason University
|
|
Address:
|
23044 Winged Elm Drive, Clarksburg, MD, 20871,
|
|
Keywords:
|
clinical effectiveness ; rimonabant
|
|
Abstract:
|
Obesity is the most common nutritional disorder in western industrialized countries and arises from the accumulation of excess fat in the body from over consumption of fatty foods. The prevalence of obesity and diabetes is increasing dramatically in the Sates and worldwide. Obesity is a major risk factor for diabetes, cardiovascular disease, and metabolic syndrome. The metabolic syndrome is a precursor to cardiovascular disease and diabetes. The endocannabinoid system controls food intake via both central and peripheral mechanisms. The cannabinoid receptor antagonist effect has a broad impact on metabolism and is associated with several sites of action and mechanisms. The administration of CB1 antagonists has several clinical implications. Blockade of the endocannabinoid system has therapeutic potential in the management of obesity and cardiometabolic risk.
|
